Department of Gerontology, Federal University of São Carlos, São Carlos, SP, Brazil.
Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
J Alzheimers Dis. 2018;61(1):113-123. doi: 10.3233/JAD-170592.
ADAM10 is the α-secretase that cleaves amyloid-β protein precursor in the non-amyloidogenic pathway in Alzheimer's disease (AD) and is known to be regulated by different microRNAs (miRNAs), which are post-transcriptional regulators related to several biological and pathological processes, including AD. Here we proposed to explore and validate miRNAs that have direct or indirect relations to the AD pathophysiology and ADAM10 gene. Approximately 700 miRNAs were analyzed and 21 differentially expressed miRNAs were validated in a sample of 21 AD subjects and 17 cognitively healthy matched controls. SH-SY5Y cells were transfected with miR-144-5p, miR-221, and miR-374 mimics and inhibitors, and ADAM10 protein levels were evaluated. miR-144-5p, miR-221, and miR-374 were downregulated in AD. The overexpression of miR-221 in SH-SY5Y cells resulted in ADAM10 reduction and its inhibition in ADAM10 increased. These findings show that miR-221 can be a new potential therapeutic target for increasing ADAM10 levels in AD. In addition, these results can contribute to the better understanding of ADAM10 post-transcriptional regulation.
ADAM10 是阿尔茨海默病(AD)中非淀粉样蛋白生成途径中切割淀粉样β蛋白前体的 α-分泌酶,已知其受到不同 microRNAs(miRNAs)的调节,miRNAs 是与包括 AD 在内的多种生物学和病理过程相关的转录后调控因子。在这里,我们提出探索和验证与 AD 病理生理学和 ADAM10 基因有直接或间接关系的 miRNAs。在 21 名 AD 患者和 17 名认知健康匹配对照者的样本中分析了大约 700 个 miRNAs,验证了 21 个差异表达的 miRNAs。用 miR-144-5p、miR-221 和 miR-374 的模拟物和抑制剂转染 SH-SY5Y 细胞,并评估 ADAM10 蛋白水平。AD 中 miR-144-5p、miR-221 和 miR-374 下调。SH-SY5Y 细胞中 miR-221 的过表达导致 ADAM10 减少,而其抑制则增加了 ADAM10。这些发现表明,miR-221 可能是增加 AD 中 ADAM10 水平的新的潜在治疗靶点。此外,这些结果有助于更好地理解 ADAM10 的转录后调控。